{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T02:42:23Z","timestamp":1786502543145,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T00:00:00Z","timestamp":1689724800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Patient Rep Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) are rare inherited retinal degenerative disorders. The associated visual impairments have significant impacts on patients\u2019 vision-dependent activities of daily living (ADL), mobility, and distal health-related quality of life (HRQoL). To adequately capture patient and caregiver perspectives in clinical trials, patient and observer-reported outcome instruments must demonstrate sufficient evidence of content validity in the target population. This study aimed to explore the patient experience of RP\/LCA and assess the content validity of the Visual Symptom and Impact Outcomes PRO (ViSIO-PRO) and ObsRO (ViSIO-ObsRO) instruments in RP\/LCA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 66 qualitative, combined concept elicitation (CE) and cognitive debriefing (CD) interviews were conducted (33 adults, 10 adolescents, 8 children and 15 caregivers of children) in the US, France, Germany, and Canada. Patients had a clinical and genetic diagnosis of RP\/LCA from a range of genotypes. CE results were used to further inform the development of a conceptual model and CD interviews assessed the relevance and understanding of the 44-item ViSIO-PRO and 26-item ViSIO-ObsRO instruments. Interviews were conducted across two iterative rounds to allow item modifications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Findings were consistent across RP\/LCA genotypes. Night blindness, reduced peripheral vision, vision in very bright lighting and light\/dark adaptation were the most frequently reported visual function symptoms impacting vision-dependent ADL and mobility. Impacts on distal HRQoL domains were also reported. The ViSIO-PRO and ObsRO items were well understood by participants and relevant across genotypes. The instructions, 7-day recall period and response scales were well understood and endorsed. Participant and expert clinician feedback supported modifications to item wording, the addition of six new ViSIO-PRO items and one new ViSIO-ObsRO item, and the removal of one ViSIO-PRO item due to lack of relevance.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Findings support the content validity of the ViSIO-PRO and ViSIO-ObsRO instruments for use across RP\/LCA genotypes. Ongoing research to evaluate the psychometric validity of the instruments will support future use of the instruments as efficacy endpoints in clinical trials and in general clinical practice to track disease severity and impact of disease on functioning.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s41687-023-00610-x","type":"journal-article","created":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T13:02:05Z","timestamp":1689771725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Qualitative exploration of the visual function impairments and impacts on vision-dependent activities of daily living in Retinitis Pigmentosa and Leber Congenital Amaurosis: content validation of the ViSIO-PRO and ViSIO-ObsRO measures"],"prefix":"10.1186","volume":"7","author":[{"given":"Christine","family":"Kay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Audo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Naujoks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Spera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Dominik","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Durham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Barclay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joel","family":"Sims","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judit","family":"Banhazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Patalano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,19]]},"reference":[{"issue":"10","key":"610_CR1","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1093\/hmg\/11.10.1219","volume":"11","author":"C Rivolta","year":"2002","unstructured":"Rivolta C, Sharon D, DeAngelis MM, Dryja TP (2002) Retinitis pigmentosa and allied diseases: numerous diseases, genes, and inheritance patterns. Hum Mol Genet 11(10):1219\u20131227","journal-title":"Hum Mol Genet"},{"issue":"4","key":"610_CR2","doi-asserted-by":"publisher","first-page":"238","DOI":"10.2174\/138920211795860107","volume":"12","author":"S Ferrari","year":"2011","unstructured":"Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F (2011) Retinitis pigmentosa: genes and disease mechanisms. Curr Genom 12(4):238\u2013249","journal-title":"Curr Genom"},{"issue":"9549","key":"610_CR3","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1016\/S0140-6736(06)69740-7","volume":"368","author":"DT Hartong","year":"2006","unstructured":"Hartong DT, Berson EL, Dryja TP (2006) Retinitis pigmentosa. The Lancet 368(9549):1795\u20131809","journal-title":"The Lancet"},{"key":"610_CR4","unstructured":"Fahim ATDS, Weleber RG (1993\u20132020) Nonsyndromic retinitis pigmentosa overview. In: Adam MP, Ardinger HH, Pagon RA et al (eds) GeneReviews. University of Washington, Seattle. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK1417\/ed.2017"},{"issue":"4","key":"610_CR5","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/138920211795860116","volume":"12","author":"S Chang","year":"2011","unstructured":"Chang S, Vaccarella L, Olatunji S, Cebulla C, Christoforidis J (2011) Diagnostic challenges in retinitis pigmentosa: genotypic multiplicity and phenotypic variability. Curr Genom 12(4):267\u2013275","journal-title":"Curr Genom"},{"issue":"6","key":"610_CR6","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1007\/s12325-020-01275-4","volume":"37","author":"J Green","year":"2020","unstructured":"Green J, Tolley C, Bentley S et al (2020) Qualitative interviews to better understand the patient experience and evaluate patient-reported outcomes (PRO) in RLBP1 retinitis pigmentosa (RLBP1 RP). Adv Ther 37(6):2884\u20132901","journal-title":"Adv Ther"},{"issue":"11","key":"610_CR7","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1001\/archopht.116.11.1496","volume":"116","author":"CM Mangione","year":"1998","unstructured":"Mangione CM, Lee PP, Pitts J, Gutierrez P, Berry S, Hays RD (1998) Psychometric properties of the National Eye Institute visual function questionnaire (NEI-VFQ). Arch Ophthalmol 116(11):1496\u20131504","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"610_CR8","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1001\/archopht.119.7.1050","volume":"119","author":"CM Mangione","year":"2001","unstructured":"Mangione CM, Lee PP, Gutierrez PR, Spritzer K, Berry S, Hays RD (2001) Development of the 25-list-item national eye institute visual function questionnaire. Arch Ophthalmol 119(7):1050\u20131058","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"610_CR9","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1167\/iovs.05-1222","volume":"47","author":"C Owsley","year":"2006","unstructured":"Owsley C, McGwin G, Scilley K, Kallies K (2006) Development of a questionnaire to assess vision problems under low luminance in age-related maculopathy. Investig Ophthalmol Vis Sci 47(2):528\u2013535","journal-title":"Investig Ophthalmol Vis Sci"},{"key":"610_CR10","first-page":"26","volume":"1","author":"M Sloane","year":"1992","unstructured":"Sloane M, Ball K, Owsley C, Bruni J, Roenker D (1992) The Visual Activities Questionnaire: developing an instrument for assessing problems in everyday visual tasks. Tech Digest Noninvasive Assess Vis Syst 1:26\u201329","journal-title":"Tech Digest Noninvasive Assess Vis Syst"},{"key":"610_CR11","unstructured":"Food and Drug Administration (2009) Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims"},{"key":"610_CR12","unstructured":"Food and Drug Administration (2020) FDA patient-focused drug development guidance series for enhancing the incorporation of the patient\u2019s voice in medical product development and regulatory decision making. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/fda-patient-focused-drug-development-guidance-series-enhancing-incorporation-patients-voice-medical. Published 2020. Accessed."},{"issue":"9","key":"610_CR13","doi-asserted-by":"publisher","first-page":"A761","DOI":"10.1016\/j.jval.2017.08.2157","volume":"20","author":"C Tolley","year":"2017","unstructured":"Tolley C, Mullins A, Kilgariff S et al (2017) Qualitative interviews to inform development of a patient reported outcome (PRO) strategy In RLBP1 retinitis pigmentosa (RLBP1 RP). Value Health 20(9):A761","journal-title":"Value Health"},{"key":"610_CR14","doi-asserted-by":"crossref","unstructured":"Green J, Williamson N, Bradley H et al (2021) Qualitative exploration of patient experiences of visual function impairments and health-related quality of life impacts associated with RLBP1 retinitis pigmentosa in a sample of Canadian patients. Virtual poster presentation presented at ISPOR 2021","DOI":"10.1016\/j.jval.2021.04.1115"},{"key":"610_CR15","unstructured":"Audo I, Williamson N, Bradley H et al (2021) Qualitative exploration of patient and caregiver experiences of visual function impairments and impacts on vision-dependent activities of daily living and health-related quality of life associated with Retinitis Pigmentosa and Leber Congenital Amaurosis in Germany and France. Virtual poster presentation presented at ARVO 2021"},{"issue":"9","key":"610_CR16","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1177\/1049732305276687","volume":"15","author":"HF Hsieh","year":"2005","unstructured":"Hsieh HF, Shannon SE (2005) Three approaches to qualitative content analysis. Qual Health Res 15(9):1277\u20131288","journal-title":"Qual Health Res"},{"issue":"4","key":"610_CR17","doi-asserted-by":"publisher","first-page":"436","DOI":"10.2307\/798843","volume":"12","author":"BG Glaser","year":"1965","unstructured":"Glaser BG (1965) The constant comparative method of qualitative analysis. Soc Probl 12(4):436\u2013445","journal-title":"Soc Probl"},{"issue":"10","key":"610_CR18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C et al (2010) What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health 25(10):1229\u20131245","journal-title":"Psychol Health"},{"issue":"1","key":"610_CR19","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L (2006) How many interviews are enough? An experiment with data saturation and variability. Field Methods 18(1):59\u201382","journal-title":"Field Methods"},{"issue":"3","key":"610_CR20","doi-asserted-by":"publisher","first-page":"A33","DOI":"10.1016\/j.jval.2015.03.198","volume":"18","author":"RE Lamoureux","year":"2015","unstructured":"Lamoureux RE, Shields A, Stokes J, Yaworsky A, Galipeau N (2015) How many subjects are enough for symptom-focused concept elicitation studies? A retrospective analysis of saturation across twenty-six studies. Value Health 18(3):A33","journal-title":"Value Health"},{"issue":"7","key":"610_CR21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.jval.2017.11.014","volume":"21","author":"DM Turner-Bowker","year":"2018","unstructured":"Turner-Bowker DM, Lamoureux RE, Stokes J et al (2018) Informing a priori sample size estimation in qualitative concept elicitation interview studies for clinical outcome assessment instrument development. Value Health 21(7):839\u2013842","journal-title":"Value Health"},{"key":"610_CR22","unstructured":"Atlas.Ti. Atlas.Ti software version 8 (Atlas.Ti Scientific Software Development GmbH, Berlin, Germany) (2016)"},{"issue":"2","key":"610_CR23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V (2006) Using thematic analysis in psychology. Qual Res Psychol 3(2):77\u2013101","journal-title":"Qual Res Psychol"},{"issue":"3","key":"610_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","volume":"10","author":"C Kerr","year":"2010","unstructured":"Kerr C, Nixon A, Wild D (2010) Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. Expert Rev Pharmacoecon Outcomes Res 10(3):269\u2013281","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"610_CR25","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1177\/1525822X05279903","volume":"18","author":"G Guest","year":"2006","unstructured":"Guest G, Bunce A, Johnson L (2006) How many interviews are enough? An experiment with data saturation and variability. Field Methods 18:59\u201382","journal-title":"Field Methods"},{"issue":"4","key":"610_CR26","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1136\/bjo.85.4.432","volume":"85","author":"DA Rosser","year":"2001","unstructured":"Rosser DA, Laidlaw DA, Murdoch IE (2001) The development of a \u201creduced logMAR\u201d visual acuity chart for use in routine clinical practice. Br J Ophthalmol 85(4):432\u2013436","journal-title":"Br J Ophthalmol"},{"key":"610_CR27","unstructured":"Audo I, Patalano F, Naujoks C et al (2022) Qualitative exploration of visual function impairments and impacts on vision-dependent activities of daily living of Retinitis Pigmentosa to support development of patient-reported outcome (PRO) and observer-reported outcome (ObsRO) instruments. [UNPUBLISHED]"},{"key":"610_CR28","doi-asserted-by":"publisher","unstructured":"Lacy GD, Abalem MF, Andrews CA, Popova LT, Santos EP, Yu G, Rakine HY, Baig N, Ehrlich JR, Fahim AT, Branham KH, Stelmack JA, Swenor BK, Dagnelie G, Musch DC, Jayasundera KT. The michigan retinal degeneration questionnaire: a patient-reported outcome instrument for inherited retinal degenerations. Am J Ophthalmol. 2021;222:60\u201368. https:\/\/doi.org\/10.1016\/j.ajo.2020.08.032.","DOI":"10.1016\/j.ajo.2020.08.032"},{"issue":"7","key":"610_CR29","first-page":"1564","volume":"61","author":"G Lacy","year":"2020","unstructured":"Lacy G, Abalem MF, Baig N et al (2020) Development of a validated patient-reported outcomes measure for retinal dystrophy therapeutics. Invest Ophthalmol Vis Sci 61(7):1564\u20131564","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Journal of Patient-Reported Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00610-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41687-023-00610-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41687-023-00610-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,19]],"date-time":"2023-07-19T13:05:42Z","timestamp":1689771942000},"score":1,"resource":{"primary":{"URL":"https:\/\/jpro.springeropen.com\/articles\/10.1186\/s41687-023-00610-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["610"],"URL":"https:\/\/doi.org\/10.1186\/s41687-023-00610-x","relation":{},"ISSN":["2509-8020"],"issn-type":[{"value":"2509-8020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,19]]},"assertion":[{"value":"5 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by a centralised independent review board in the US (approval number: 20190129) and by local ethical review boards in France, Germany, and Canada prior to the conduct of any study-related activities. All participants provided informed consent before participating in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Christel Naujoks, Claudio Spera, Judit Banhazi and Francesco Patalano are employees of Novartis Pharma AG. Nicola Williamson, Helena Bradley, Melissa Barclay and Joel Sims are employees of Adelphi Values, a health outcomes agency commissioned to conduct research by companies in the pharmaceuticals industry. Adelphi Values received funding from Novartis to conduct the research summarized in this article. Todd Durham was employed by Novartis as an advisor and received a fee for their involvement. Professors Fischer, Audo and Dr Jane Green were paid consultants of Adelphi Values on behalf of Novartis as scientific advisors and received a fee for their involvement. Professor Fischer further reports consulting fees from Advent France Biotechnology, Alphasights, Atheneum, Axiom Healthcare Strategies, Biogen, Decision Resources, Dialectica, Frontera Therapeutics, Janssen Research & Development, Navigant, Novartis, Roche, Sirion, STZ eyetrial. Professor Audo is also a consultant for Novartis, Sparing Vision, Roche, 4DMT and Biogen. Dr. Kay reports consultancy\/investigator fees from AGTC, Foundation Fighting Blindness, Alkeus, Gyroscope, REGENXBIO, Nightstar Therapeutics\/Biogen, Spark therapeutics, Novartis, Iveric Bio, ProQR Therapeutics, MeiraGTx, Janssen, Atsena Therapeutics, 4D Molecular Therapeutics and Kodiak. The authors declare that there are no other competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}